Ixekizumab is superior to placebo for the treatment of nail, scalp, and palmoplantar psoriasis in pediatric patients with moderate to severe plaque psoriasis

被引：0

作者：

Paller, Amy S. ^{[1
]}

Magarinos, Gabriel Alejandro ^{[1
]}

Pinter, Andreas ^{[1
]}

Cather, Jennifer ^{[1
]}

Keller, Stuart ^{[1
]}

Capriles, Claudia Rodriguez ^{[1
]}

Gallo, Gaia ^{[1
]}

Edson-Heredia, Emily ^{[1
]}

Li, Lingnan ^{[1
]}

Papp, Kim ^{[1
]}

机构：

[1] Northwestern Med, Chicago, IL USA

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2020年 / 83卷 / 06期

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

14161

引用

页码：AB20 / AB20

页数：1

共 50 条

[21] Risankizumab profile in nail, scalp and palmoplantar psoriasis: efficacy and safety at 52 weeks in an integrated analysis of patients wth moderate-tosevere plaque psoriasis
Reich, Kristian
Ryan, Caitriona
Crowley, Jeffrey
Szepietowski, Jacek C.
Zeng, Jiewei
Valdes, Joaquin
Photowala, Huzefa
Kaufman, Christian
Gooderham, Melinda
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2020, 18 : 17 - 18
[22] Improvement in nail psoriasis in the open-label extension period of a phase 2 trial of ixekizumab in patients with moderate-to-severe plaque psoriasis
Rich, P.
Langley, R. G.
Menter, A.
Krueger, G. G.
Zhu, B.
Wei, H.
Cameron, G. S.
Heffernan, M. P.
Holzkaemper, T.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2015, 13 : 135 - 136
[23] Improvement in nail psoriasis in the open-label extension of a phase-2 trial of ixekizumab in patients with moderate-to-severe plaque psoriasis
McKevitt, N.
Rich, P.
Langley, R. G.
Menter, A.
Krueger, G.
Zhu, B.
Wei, H.
Cameron, G. S.
Heffernan, M. P.
AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2015, 56 : 50 - 50
[24] Comparison of a selective IL-23p19 inhibitor (BI 655066) with ustekinumab in patients with moderate-to-severe plaque psoriasis: Analysis of scalp, palmoplantar, and nail psoriasis subgroups
Papp, Kim A.
Blauvelt, Andrew
Bukhalo, Michael
Gooderham, Melinda
Lacour, Jean-Philippe
Menter, Alan
Philipp, Sandra
Sofen, Howard
Tyring, Stephen
Berner, Beate
Bennett, Nathan
Flack, Mary
Scholl, Paul
Padula, Steven
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB240 - AB240
[25] Efficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis
Saeki, H.
Nakagawa, H.
Ishii, T.
Morisaki, Y.
Aoki, T.
Berclaz, P. -Y.
Heffernan, M.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2015, 29 (06) : 1148 - 1155
[26] Ixekizumab in the treatment of moderate-to-severe plaque psoriasis: Patient adherence, satisfaction, and preferences
Azhar, Aaminah
Zaayman, Marcus
Silfvast-Kaiser, Annika
Kivelevitch, Dario
Menter, Alan
Paek, So Yeon
DERMATOLOGIC THERAPY, 2021, 34 (01)
[27] Ixekizumab treatment in patients with moderate-to-severe plaque psoriasis in a real-world clinical setting
Ogut, Neslihan Demirel
Yildirim, Sema Koc
Erbagci, Ece
Hapa, Fatma Asli
JOURNAL OF COSMETIC DERMATOLOGY, 2022, 21 (11) : 6215 - 6224
[28] Ixekizumab: A Review of Its Use for the Management of Moderate to Severe Plaque Psoriasis
Shelton, Sydney K.
Bai, Sandra R.
Jordan, Joseph K.
Sheehan, Amy Heck
ANNALS OF PHARMACOTHERAPY, 2019, 53 (03) : 276 - 284
[29] Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis
Gordon, K. B.
Blauvelt, A.
Papp, K. A.
Langley, R. G.
Luger, T.
Ohtsuki, M.
Reich, K.
Amato, D.
Ball, S. G.
Braun, D. K.
Cameron, G. S.
Erickson, J.
Konrad, R. J.
Muram, T. M.
Nickoloff, B. J.
Osuntokun, O. O.
Secrest, R. J.
Zhao, F.
Mallbris, L.
Leonardi, C. L.
NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (04): : 345 - 356
[30] Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and comorbid diabetes mellitus
Egeberg, A.
Schaekel, K.
Puig, L.
Saure, D.
Yali Wang, I.
Pavo, I.
Mahar, P.
Schuster, C.
Griffiths, C. E. M.
BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (01) : E31 - E31

← 1 2 3 4 5 →